small win: dose escalation stopped being a problem at week 19
small win: dose escalation stopped being a problem at week 19. This is a description of what happened to me and not a plan for anybody else.
What the glucagon arm is doing, as best anyone can say from public data.
GLP-1 and GIP agonism cover appetite and insulin secretion in ways that are now reasonably well characterised. Glucagon receptor agonism is the third leg and it is associated with increased energy expenditure and with effects on hepatic fat.
Mechanistically that is why this compound reads as a different proposition rather than a stronger version of a dual agonist. Clinically, the size and durability of that difference in humans is precisely what is not yet established, and anyone telling you otherwise is filling a gap with confidence.
Where the evidence actually stands, since every thread here assumes a different answer.
Phase 2 reported a large mean body weight change at 48 weeks across a few hundred participants with a slow, protocol-driven escalation. The effect size was striking. The confidence intervals were wide, the population was small, and the duration was under a year.
Phase 3 is running. Until it reports, everything else — including the ranking arguments this board loves — is extrapolation from a small study. That is not a criticism of the compound; it is a description of the evidence.
Please do not ask me what dose you should be on. I genuinely do not know and neither does anyone else here.
best — the order this archive was captured in
The standing caveat, written out properly because it keeps getting compressed into a footnote.
Nothing containing this compound is approved by any regulator. Research-use-only material is not approved for human use. That is not a legal formality on this board — it is why there is so little independent data, why the escalation schedules people post are invented, and why nobody here can answer a dosing question.
What this board can usefully do is read the published trials carefully, log independent purity results, and be honest about how thin the evidence base is. Everything else belongs somewhere with a clinician in it.
nothing here is available as a prescription product, so read every thread with that in mind
The standing caveat, written out properly because it keeps getting compressed into a footnote.
This is the sentence the rest of the board should read first. Phase 2 is not a label.
What is the source for that figure — the published paper or a summary of it?
Cosigning the escalation point. Almost every difficult report on this board is from somebody who went up quickly.
It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.
Careful with the rankings. A phase 2 result and a phase 3 result are not on the same evidential footing and cannot be listed in one table.
Yes — the comparison threads are apples to oranges and they generate more heat than anything else here.
Read the phase 2 paper twice before ordering anything. Recommend that to anyone in this board: the error bars are the interesting part.
Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use, and that is a statement of fact rather than a disclaimer.
Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects. That is a mechanistic story with strong preclinical support and limited phase 2 human data.
Push back: quoting the phase 2 headline as an expected outcome is not a fair reading of a small trial with wide intervals.
Same read. The energy-expenditure mechanism is the interesting bit and it is not established in humans at scale.
The reflux profile felt different rather than worse. Hard to describe and impossible to quantify, so take it as an impression.
Independent purity testing on this compound is thin compared with the older molecules, simply because fewer members have paid for it. Fewer results means wider uncertainty, not a verdict.
Right, and it bears repeating that nothing here is approved anywhere and research material is not for human use.
Not convinced. You are attributing a week of early fullness to the glucagon arm when the escalation rate alone would explain it.